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The TPR Domain in the Host Cyp40-like Cyclophilin Binds
to the Viral Replication Protein and Inhibits the
Assembly of the Tombusviral Replicase
Jing-Yi Lin, Venugopal Mendu., Judit Pogany., Jun Qin¤, Peter D. Nagy*
Department of Plant Pathology, University of Kentucky, Lexington, Kentucky, United States of America
Abstract
Replication of plus-stranded RNA viruses is greatly affected by numerous host-coded proteins acting either as susceptibility
or resistance factors. Previous genome-wide screens and global proteomics approaches with Tomato bushy stunt
tombusvirus (TBSV) in a yeast model host revealed the involvement of cyclophilins, which are a large family of host prolyl
isomerases, in TBSV replication. In this paper, we identified those members of the large cyclophilin family that interacted
with the viral replication proteins and inhibited TBSV replication. Further characterization of the most effective cyclophilin,
the Cyp40-like Cpr7p, revealed that it strongly inhibits many steps during TBSV replication in a cell-free replication assay.
These steps include viral RNA recruitment inhibited via binding of Cpr7p to the RNA-binding region of the viral replication
protein; the assembly of the viral replicase complex and viral RNA synthesis. Since the TPR (tetratricopeptide repeats)
domain, but not the catalytic domain of Cpr7p is needed for the inhibitory effect on TBSV replication, it seems that the
chaperone activity of Cpr7p provides the negative regulatory function. We also show that three Cyp40-like proteins from
plants can inhibit TBSV replication in vitro and Cpr7p is also effective against Nodamura virus, an insect pathogen. Overall,
the current work revealed a role for Cyp40-like proteins and their TPR domains as regulators of RNA virus replication.
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Introduction
Replication of plus-stranded (+)RNA viruses takes place in
membrane-bound viral replicase complexes (VRCs) in the
cytoplasm of infected cells. (+)RNA viruses usurp a number of
host-coded proteins to aid the replication process [1–8]. Many
host proteins, however, have antiviral activities by inhibiting
various steps of viral replication and infection. Accordingly,
genome-wide screens to identify host factors affecting (+)RNA
virus infections, such as Tomato bushy stunt virus (TBSV), West Nile
virus, Brome mosaic virus (BMV), Hepatitis C virus (HCV), Dengue
virus and Droshophila virus C in yeast or animal cells led to the
identification of stimulatory as well as inhibitory host proteins [9–
17]. The functions of the majority of the identified host proteins in
(+)RNA virus replication have not been fully revealed.
TBSV is a small (+)RNA virus that has recently emerged as a
model virus to study virus replication, recombination, and virus -
host interactions due to the development of yeast (Saccharomyces
cerevisiae) as a model host [18–21]. Genome-wide screens of yeast
genes and global proteomics approaches have led to the
identification of over 300 host genes/proteins that affected either
TBSV replication or recombination [9,11,22,23]. Also, proteomics
analysis of the highly purified tombusvirus replicase complex
revealed the presence of the two viral replication proteins (i.e., p33
and p92pol) and 6–10 host proteins in VRC [24,25,26]. These host
proteins have been shown to bind to the viral RNA and the viral
replication proteins [1,25,27]. For example, heat shock protein 70
(Hsp70), eukaryotic elongation factor 1A (eEF1A) and the ESCRT
(endosomal sorting complexes required for transport) family of
host proteins are required for the assembly of VRC, while
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and eEF1A
have been shown to affect viral RNA synthesis [27–31]. The
auxiliary p33 replication protein has been shown to recruit the
TBSV (+)RNA to the site of replication, which is the cytosolic
surface of peroxisomal membranes [32–34]. The RdRp protein
p92pol binds to the essential p33 replication protein that is required
for assembling the functional VRC [20,34–36]. In contrast, the
roles of identified host proteins with inhibitory functions in TBSV
replication are less characterized. Nucleolin, an RNA binding
protein, has been shown to interfere with the recruitment of the
viral RNA into replication [37], while Rsp5p, a Nedd4 family of
E3 ubiquitin ligase, regulates the degradation of p92pol in yeast
cells and the activity of VRC in vitro [38]. In addition, Cpr1p
cyclophilin and Ess1p parvulin also decrease TBSV RNA
accumulation in yeast, but the mechanism is not yet unraveled
[39].
Cyclophilin family of proteins are ubiquitous, highly conserved
proteins with prolyl isomerase (PPIase) activity. Cyclophilins and
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the structurally unrelated FKB proteins (FK506-binding proteins)
and parvulins constitute a family of 13 prolyl isomerases in yeast.
These proteins catalyze cis-trans isomerization of the peptidyl-
prolyl bonds that could alter the structure, function or localization
of the client proteins [40–41]. The isomerization of the peptidyl-
prolyl bonds are frequently required for protein refolding after
trafficking through cellular membranes [41]. The best-known
member of prolyl isomerases in eukaryotes is cyclophilin A (CypA
in mammals and Cpr1p in yeast). The most important functions of
cyclophilins in cells are in protein folding, assembly of multido-
main proteins, muscle differentiation, detoxification of reactive
oxygen species, and immune response. Cyclophilins have been
implicated in various diseases, such as cancer, atherosclerosis,
diabetes and neurodegenerative diseases [40,42,43]. Because of
their roles in immunosuppression, cyclophilins and FKBs are also
called immunophilins.
To determine the mechanism of cyclophilin-based inhibition of
tombusvirus replication, in this work, we first identified those
cyclophilins, which interacted with the TBSV p33 replication
protein, followed by testing the effect of cyclophilins in a cell-free
tombusvirus replication assay. Further analysis of Cpr7p, which,
among cyclophilins, is the strongest inhibitor of TBSV replication
in yeast and in vitro, revealed that it binds to the RNA-binding
domain of p33. This binding by Cpr7p, via its TPR (tetra-
tricopeptide repeats) domain, leads to inhibition of p33/p92-based
recruitment of the TBSV RNA for replication and decreases the
efficiency of the VRC assembly. Thus, Cpr7p is a negative
regulator of TBSV replication. We also show that Cpr7p can
inhibit the replication of the insect alfanodaviruses in yeast model
host, suggesting that Cyp40-like cyclophilins might have broad
antiviral activities during RNA virus infections.
Results
Potent inhibition of TBSV replication in a cell-free
replication assay by the p33-interacting members of the
cyclophilin family
A previous screen based on MYTH (membrane yeast two-
hybrid) split-ubiquitin assay and a yeast cDNA library has
identified Cpr1 cyclophilin (CypA-like) as a strong interactor with
p33 replication protein [39]. Since cyclophilins, together with the
structurally unrelated FKB proteins and parvulins, constitute a
family of 13 prolyl isomerases in yeast, we wanted to know if other
members of PPIases could also interact with the TBSV replication
proteins. The MYTH assay revealed that 6 members of the
cyclophilin family, namely Cpr1p, Cpr3p, Cpr6p, Cpr7p, Fpr1p
(Figure 1A) and Ess1p [39], interact with p33 replication protein.
To test if cyclophilins can directly affect the activity of the
tombusvirus replicase, we prepared cell-free extracts (CFE) from
yeast strains with deletion of multiple cyclophilin genes (Figure 1B).
These yeast extracts contained comparable amount of total
proteins (not shown) or an ER-resident marker protein [Dpm1p,
[29]] (Figure 1C). The advantage of the CFE extract-based TBSV
replication assay is that the CFE can be programmed with the
TBSV (+)repRNA in the presence of purified recombinant p33
and p92pol obtained from E. coli that leads to the in vitro assembly of
the viral replicase, followed by a single cycle of complete TBSV
replication, resulting in both (2)-stranded and (+)-stranded
repRNA progeny [31,35].
Using CFE prepared from a yeast strain missing all 8 CPR and 4
FPR genes (ESS1 is an essential gene and thus it could not be
deleted) resulted in ,7-fold increase in TBSV repRNA accumu-
lation in vitro (Figure 1C, lanes 9–10). This result firmly established
that in general cyclophilins are strong inhibitors of TBSV
replication. Using CFEs from yeast missing all 8 CPR genes also
resulted in ,5.5-fold increase in TBSV repRNA accumulation in
vitro (Figure 1C, lanes 5–6). In contrast, CFE missing all 4 FPR
genes supported TBSV replication only a little better than CFE
from wt yeast (Figure 1C, lanes 3–4), suggesting that FPRs are not
as important inhibitory proteins as CPRs. Also, CFE missing the
five cyclophilins that interact with p33 (i.e., Cpr1p, Cpr3p, Cpr6p,
Cpr7p, Fpr1p) supported TBSV replication ,6.5-fold more
efficiently than wt (Figure 1C, lanes 11–12), while deletion of
those that do not interact (Cpr2p, Cpr4p, Cpr5p, Cpr8p, Fpr2p)
resulted in close to wt level of TBSV replication (Figure 1C, lanes
7–8), suggesting that only the p33-interacting cyclophilins are
important for inhibition of TBSV replication in vitro.
The TPR domain of CPR7 is a potent inhibitor of
tombusvirus replication
To identify which CPRs are the most potent inhibitors of TBSV
replication, first we have tested TBSV repRNA replication in CFE
when purified recombinant cyclophilins were separately added to
the reaction. These CFE-based experiments revealed that
recombinant Cpr3p and Cpr7p inhibited (Figure S1A, lanes 9–
14), while Cpr1p (lanes 6–8) and Cpr6p (Figure S1C, lanes 6–8)
did not inhibit TBSV repRNA accumulation in vitro. Additional
testing of TBSV repRNA accumulation in single and double CPR
deletion yeast strains revealed that CPR7 is the strongest inhibitor
(Figure 2 and not shown). Indeed, we observed that deletion of
CPR7, which is a Cyp40-like cyclophilin that carries both the
catalytic Cyp and TPR domains (involved in protein-protein
interactions), in yeast resulted in the largest, ,2–2.5-fold increase
in TBSV repRNA accumulation (Figure 2A–B) among the single
deletion strains (Figure 2 and not shown) [39]. Interestingly,
deletion of CPR6, which is the second member of the Cyp40-like
yeast cyclophilins, did not affect TBSV replication (Figure 2A–B),
suggesting that, in spite of the similarities in protein sequence,
CPR7 and CPR6 do not have overlapping function in inhibition of
TBSV accumulation. This conclusion was further strengthened by
the double-deletion yeast strain (cpr6D cpr7D), which supported
TBSV accumulation at ,2–3-fold higher level than that in the
WT yeast, similar to the level seen in cpr7D (Figure 2A–B).
To measure the direct effect of Cpr7p on TBSV RNA
accumulation, we performed CFE-based TBSV replication assays
with added purified recombinant Cpr7p. The inhibition of TBSV
RNA replication by Cpr7p reached up to 92% in vitro (Figure 3A,
lane 8). The purified TPR domain of Cpr7p was even more potent
inhibitor of TBSV replication in vitro (Figure 3A, lanes 12–14) than
Author Summary
Replication of plus-stranded RNA viruses, which are
important pathogens of humans, animals and plants, can
be inhibited by host-coded proteins. In this paper, the
authors show that the Cyp40-like Cpr7p prolyl isomerase
of yeast can effectively inhibit tombusvirus replication. This
inhibition is due to binding of the TPR (tetratricopeptide
repeats) domain of Cpr7p to the RNA-binding region of
the tombusvirus replication proteins that leads to inhibi-
tion of RNA binding by the viral replication proteins,
interference with the assembly of the viral replicase and
blocking viral RNA synthesis. Cpr7p is also effective against
the distantly-related alfanodaviruses of insects. Overall, this
work reveals a role for a Cyp40-like protein as a regulator
of RNA virus replication. This function of Cyp40 during RNA
virus infection seems to be conserved between yeast and
plants.
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Figure 1. Identification of the members of the cyclophilin (immunophilin) family that interact with p33 and inhibit TBSV replication
in vitro. (A) Split ubiquitin MYTH assay was used to test binding between p33 and the shown full-length yeast proteins. The bait p33 was co-
expressed with the prey proteins in yeast. SSA1 (HSP70 chaperone), and the empty prey vector (NubG) were used as positive and negative controls,
respectively. The interaction of cyclophilins with p33, their localization in cells and human homologs are summarized below the image. (B) Scheme of
the CFE-based TBSV replication assay. Purified recombinant p33 and p92pol replication proteins of TBSV and in vitro transcribed TBSV DI-72 (+)repRNA
were added to the whole cell extract prepared from various yeast strains with deletion of selected members of the immunophilin genes as shown in
panel C. (C) Top panel: Denaturing PAGE analysis of the 32P-labeled TBSV repRNA products obtained in the TBSV replication assay based on various
CFEs as shown. Each experiment was repeated three times. Bottom panel: Western blot analysis of various CFEs with anti-Dpm1 antibody, an ER-
resident protein, to show similar protein content in CFEs.
doi:10.1371/journal.ppat.1002491.g001
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the full-length protein, while the catalytic Cyp domain had a lesser
effect (up to 80%, Figure 3A, lane 11).
The MYTH-based interaction of Cpr7p and its domains with
p33 showed that the TPR domain is the strongest interactor, while
the full-length protein was also a good interactor when compared
with the Cyp-domain (Figure 3B). Thus, there seems to be
correlation between the strength of interaction and extent of
inhibition by Cpr7 and its derivatives on TBSV replication in vitro.
Interestingly, this is not the case with Cpr6p, which strongly
interacted with p33, but did not inhibit TBSV replication
effectively (Figure S2A). Data shown below in the paper, however,
can explain why CPR6 deletion in yeast did not increase TBSV
replication as much as deletion of CPR7.
The Cyp40-like proteins and their TPR domains from
Arabidopsis are inhibitors of tombusvirus replication
To determine if plant Cyp40-like proteins can also inhibit
tombusvirus replication, we cloned, expressed and purified the
TPR domains of three Arabidopsis thaliana Cyp-40-like proteins and
two full-length proteins, followed by testing them in our CFE-
based TBSV replication assay (Figure S3). We found that the TPR
domains of all three Arabidopsis Cyp40 proteins inhibited TBSV
replication. The most efficient inhibitor was the full-length
At5g48570 Cyp40 protein by reducing TBSV RNA accumulation
by ,90% in vitro (Figure 3C, lane 8 versus lane 1).
The split-ubiquitin assay revealed that the TPR-domain of
At5g48570 and AtTWD1 interacted strongly with both p33 and
p92, while At2g15790 interaction was weak, but detectable (Figure
S3B–C). Altogether, these data indicate that the plant Cyp40
proteins and their TPR domains interact with TBSV p33/p92
replication proteins and At5g48570 is as potent inhibitor of
tombusvirus replication as the yeast Cpr7p.
The mechanism of CPR7-based inhibition of tombusvirus
replication
Since the recombinant Cpr7p was a potent inhibitor of TBSV
replication in vitro, we used our CFE-based approach to further
dissect the mechanism of Cpr7p-mediated inhibition. Briefly, a
Figure 2. Increased TBSV repRNA accumulation in cpr7D yeast. (A) To launch TBSV repRNA replication, we expressed 6xHis-p33 and 6xHis-p92
from the copper-inducible CUP1 promoter and DI-72(+) repRNA from the galactose-inducible GAL1 promoter in the parental (BY4741) and in cpr6D,
and cpr7D single deletion and cpr6D cpr7D double deletion yeast strains. The yeast cells were cultured for 40 hours at either 29uC (panel A) or 23uC
(panel B) on 2% galactose SC minimal media. Northern blot analysis was used to detect DI-72(+) repRNA accumulation. The accumulation level of DI-
72(+) repRNA was normalized based on 18S rRNA. Bottom panels: Western blot analysis of the accumulation level of 6xHis-tagged p33 and 6xHis-
tagged p92 proteins using anti-His antibody. Asterisk marks the SDS-resistant p33 homodimer. The Western blot for PGK host protein at the bottom
shows the loading control.
doi:10.1371/journal.ppat.1002491.g002
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two-step replication assay based on yeast CFE was used to
determine what steps of TBSV replication could be inhibited by
Cpr7p. In this assay, the first step includes the assembly of the
replicase complex on the endogenous membranes present in CFE
in the presence of the viral (+)repRNA, the recombinant p33 and
p92 replication proteins and ATP/GTP [31] (Figure 4A, step 1).
Under these conditions, the viral replication proteins recruit the
(+)repRNA to the membrane and the viral replicase becomes
partially RNase and protease insensitive. However, the assembled
replicase cannot initiate minus-strand synthesis yet, due to the
absence of CTP/UTP [31]. Then, centrifugation and washing the
membranes will remove all the proteins and molecules not bound
to the membrane. This is then followed by addition of ATP/CTP/
GTP/UTP (32P-labeled) to initiate RNA synthesis during the
second step.
Addition of purified recombinant Cpr7p to the CFE during the
first step inhibited TBSV replication up to ,80% (Figure 4B, lane
10 versus 1), similar to the strong inhibitory effect of Cpr7p during
standard CFE replication assay (Figure 3). This suggests that
Cpr7p might inhibit the assembly of the replicase complex.
Interestingly, the TPR domain was again a more potent inhibitor
(Figure 4B, lanes 14–16) than the full-length Cpr7p, while the Cyp
Figure 3. Cell-free TBSV replication assay supports an inhibitory role for Cpr7p and an Arabidopsis Cyp40 homolog. (A) Top panel:
Denaturing PAGE analysis of the 32P-labeled TBSV repRNA products obtained in the CFE-based assay programmed with in vitro transcribed TBSV DI-
72 (+)repRNA and purified recombinant p33 and p92pol replication proteins of TBSV. Purified recombinant GST-tagged Cpr7p, the Cyp domain or the
TPR domain (0.4, 0.8 and 1.6 mg), or GST were added to CFE prepared from BY4741 yeast strain. Each experiment was repeated three times. Middle
panel: Ethidium-bromide stained PAGE gel from the top panel to show the sample loading and the lack of RNase activity in the CFE-based assay.
Bottom panel: SDS-PAGE analysis of the purified recombinant proteins used in the above CFE-based assay. (B) Split ubiquitin assay was used to
demonstrate binding between p33 and the TPR and the catalytic Cyp domains of Cpr7p. The domain structure and size of Cpr7p is shown on the top.
(C) Denaturing PAGE analysis of the 32P-labeled TBSV repRNA products obtained in the CFE-based TBSV replication assay containing purified
recombinant Arabidopsis Cyp40 homolog At5g48570 and its TPR domain (0.4, 0.8 and 1.6 mg).
doi:10.1371/journal.ppat.1002491.g003
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domain was a lesser inhibitor (Figure 4B, lanes 11–13). However,
addition of Cpr7p or its truncated mutants exclusively during the
second step of the CFE assay did not inhibit TBSV RNA
replication (Figure 4C). The lack of inhibition by Cpr7p during the
second step suggests that either Cpr7p cannot inhibit RNA
synthesis by the pre-assembled replicase or Cpr7p cannot access,
and thus cannot inhibit the membrane-bound replicase (possibly
due to physical separation or constrainst by the membranous
structure).
To systemically dissect what steps in TBSV replication are
inhibited by Cpr7p, first we performed viral (+)RNA recruitment
assay (Figure 5A). The recruitment of the cytosolic TBSV
(+)repRNA to the peroxisomal or ER membrane surfaces, where
replication takes place, requires p33 and p92 replication proteins
[29,33,44]. We found the purified recombinant Cpr7p and the
TPR domain strongly inhibited the recruitment of (+)repRNA to
the membrane (Figure 5B, lanes 6–8 and 12–14 versus 1), while
the Cyp domain only had a small inhibitory effect (Figure 5B,
lanes 9–11). These data strongly support that Cpr7p can inhibit
(+)repRNA recruitment, which is critical for TBSV replication
[29,33,44].
The second test focused on the assembly of the viral replicase,
which can be performed in the CFE in the presence of ATP and
GTP (Figure 5C). Then the assembled, membrane-bound
replicase complex is solubilized with nonionic detergent, affinity-
purified, and followed by testing its activity with added TBSV
(2)repRNA [29,31]. The data show strong inhibition of replicase
activity by the full-length Cpr7p and the TPR domain (Figure 5D,
lanes 2 and 4), suggesting that these proteins inhibited the in vitro
assembly of the TBSV replicase complex in vitro.
The third assay tested the effect of recombinant Cpr7p and its
derivatives on the (+) and (2)RNA synthesis in the CFE
(Figure 5E). This assay is based on the previous observation
that the 32P-labeled (2)RNA runs as dsRNA, while the newly
Figure 4. Step-wise CFE-based TBSV replication assay supports an inhibitory role for Cpr7p in the assembly of the TBSV VRC. (A)
Scheme of the CFE-based TBSV replicase assembly and replication assays. Purified recombinant p33 and p92pol replication proteins of TBSV and in
vitro transcribed TBSV DI-72 (+)repRNA were added to CFE prepared from BY4741 yeast strain in step 1. The assay either contained or lacked the
purified recombinant Cpr7p, its derivatives (0.4, 0.8 and 1.6 mg), or GST during step 1. Note that the assay was performed in the presence of ATP/GTP
to facilitate TBSV VRC assembly, but prevent RNA synthesis in step 1. After step 1, centrifugation was used to collect the membrane fraction of the
CFE, and after washing the membranes, step 2 was performed in the presence of ATP/CTP/GTP and 32P-UTP to allow TBSV RNA replication. In the
samples presented on the right side of the panel, the recombinant Cpr7p or derivatives were added at the beginning of step 2. (B) Denaturing PAGE
analysis of the 32P-labeled TBSV repRNA products obtained in the CFE-based assays when Cpr7p or derivatives were added at the 1st step. See further
details in Figure 1. (C) Denaturing PAGE analysis of the 32P-labeled TBSV repRNA products obtained in the CFE-based assays when Cpr7p or
derivatives were added at the 2nd step. Three repeats of each experiment were performed.
doi:10.1371/journal.ppat.1002491.g004
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Figure 5. Cpr7p affects multiple steps during TBSV RNA replication in vitro. (A) Scheme of the viral RNA recruitment assay based on CFE.
The 32P-labeled TBSV (+)repRNA template was added together with p33/p92 and Cpr7p or its derivatives to CFE prepared from BY4741 yeast. The
membrane-association of 32P-labeled TBSV (+)repRNA template is measured using denaturing PAGE gels (Panel B). Note that 32P-labeled TBSV
(+)repRNA template can inefficiently associate with the membrane even in the absence of p33/p92 (lane 2), likely due to nonspecific binding to an
RNA-binding host protein in the membrane. (C) Scheme of the CFE-based TBSV replicase assembly assay. Note that the original template RNA is
removed during replicase solubilization/purification. Therefore, an added (2)repRNA is tested for replicase activity for each replicase prep. (D)
Complementary RNA synthesis that results in 32P-labeled TBSV (+)repRNA template is measured using denaturing PAGE gels. (E) Detection of single-
and double-stranded RNA products produced in the CFE-based TBSV replication assay. The ratio of ssRNA and dsRNA in the samples are shown. Note
that the dsRNA product represents the annealed 32P-labeled (2)RNA and the (+)RNA, while the ssRNA products represents the newly made 32P-
labeled (+)RNA products.
doi:10.1371/journal.ppat.1002491.g005
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made 32P-labeled (+)RNA migrates as single-stranded product in
nondenaturing PAGE [29]. The in vitro results demonstrated that
both the (+) and the (2) RNA synthesis was strongly inhibited by
the full-length Cpr7p and the TPR domain, but the ratio of
these RNAs did not change (Figure 5E). We interpret these data
that RNA synthesis was inhibited by Cpr7p, but this could be
either direct inhibition or the consequence of inhibition of the
replicase assembly step (see above), which precedes RNA
synthesis.
For the fourth assay, we utilized detergent-solubilized and
affinity-purified tombusvirus replicase from yeast (Figure 6). This
purified replicase lacks endogenous RNA, which is removed
during purification, and can only synthesize complementary
RNA products on added TBSV templates [20,25,36]. However,
unlike the above membrane-bound replicase in the CFE-based
assay, it cannot perform a complete cycle of RNA synthesis
[20,36]. The addition of purified recombinant Cpr7p to the
purified tombusvirus replicase programmed with the (2)repRNA
inhibited (+)-strand synthesis by up to ,3-fold (Figure 6A, lanes
7–9 versus 4–6). Interestingly, Cpr7p inhibited not only the
production of the full-length (+)-strand RNA product (produced
via de novo initiation), but the amount of 39-terminal extension
product (39TEX; due to self-priming by the 39 end of the
template [45,46,47]) as well. Therefore, we suggest that Cpr7p
can inhibit both de novo initiation and 39TEX on the (2)RNA
template by the tombusvirus replicase.
Pre-incubation of Cpr7p with the purified replicase preparation,
prior to the addition of the template (2)repRNA and the
ribonucleotides to start complementary RNA synthesis, resulted
in inhibition of RNA synthesis by ,2-fold (Figure 6B, lanes 7–9
versus 4–6). These data demonstrate that Cpr7p likely associates
rapidly with the tombusvirus replication proteins and pre-
incubation is not needed to increase the strong inhibitory function
of Cpr7p on tombusvirus replicase activity.
Cpr7p binds to the RNA-binding region of the p33
replication protein
To obtain information on how Cpr7p could inhibit RNA
recruitment and replicase assembly as well as block the replicase
function, we decided to map the Cpr7p binding site in the
overlapping TBSV replication proteins. To this end, we have used
pull-down experiments with immobilized MBP-p33 and its
truncation derivatives (Figure 7A) from yeast extract containing
FLAG-tagged Cpr7p. These experiments revealed that Cpr7p
binds to the arginine-proline-rich (RPR) motif in p33 (compare
pC4 and pC6 versus pC7, lanes 6,10–11, Figure 7B). Indeed,
deletion of the RPR motif inhibited p33 binding to Cpr7p
(p33CDRPR, Figure 7C, lane 3). The RPR-motif is the well-
characterized RNA-binding site in p33 and p92 replication
proteins required for specific viral RNA recruitment and replicase
assembly [33,35,44].
In contrast, Cpr6p, another Cyp40-like protein with TPR
domains, which also binds p33 replication proteins (Figure 1A),
does not bind to the RPR-motif in p33 (Figure 7C, lane 6), but
instead to a region proximal to the C-terminus (Figure S2B–C).
Based on this difference between Cpr6p and Cpr7p in binding to
p33 (and likely the overlapping p92), we propose that Cpr7p-
binding to the RPR-motif in p33 is required for the inhibitory
effect of this cyclophilin on tombusvirus replication.
Cpr7p also inhibits alfanodavirus replication in yeast
To test if replication of other RNA viruses could also be
regulated by Cyp40 proteins, first we have performed MYTH
assay with cyclophilins and replication proteins of plant and insect
Figure 6. Cpr7p inhibits complementary RNA synthesis by the
affinity-purified tombusvirus replicase. (A) Representative dena-
turing gel of 32P-labeled RNA products synthesized by the purified
tombusvirus replicase in vitro in the presence of 0.8, 1.2 and 1.6 mg of
purified recombinant Cpr7p or GST. The in vitro assays were
programmed with DI-72 (2)repRNA, and they also contained ATP/
CTP/GTP and 32P-UTP. All the components were added at the same
time. The level of complementary RNA synthesis producing ‘‘FL’’ (the
full-length product, made via initiation from the 39-terminal promoter,
also called ‘‘ti’’ product) is shown as % of FL product in the control
sample. Note that this replicase preparation also synthesizes internal
initiation products (‘‘ii’’) and 39-terminal extension products (‘‘39TEX’’).
Each experiment was repeated three times. (B) The in vitro replicase
experiment is similar to that in Panel A, except GST-Cpr7 or GST was
pre-incubated for 10 min with the replicase to facilitate binding of
Cpr7p and the VRC prior to RNA synthesis.
doi:10.1371/journal.ppat.1002491.g006
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viruses. These experiments revealed that both Cpr7p and Cpr6p
could interact with protein A of Nodamuravirus (NoV), an insect
virus, p130 replication protein of Tobacco mosaic virus (TMV) and
p28 of Turnip crinkle virus (TCV) (Figure 8A). In addition, we found
that Cpr1p (Figure S4A–D) and Cpr3p (Figure 8A) can also
interact with NoV protein A, TMV p130 and TCV p28, although
the importance of these interactions was not studied further. Then,
we tested if deletion of CPR7 and CPR6 could affect NoV and the
related Flock house virus (FHV) replication in yeast model host
[48]. Interestingly, NoV RNA replicated ,5-fold more efficiently
in cpr7D and cpr6Dcpr7D yeast when compared with the wt yeast
cells (Figure 8D, lanes 7–12 versus 1–3). Similar to TBSV, NoV
RNA also replicated only slightly better in cpr6D yeast (Figure 8D,
lanes 4–6) than the wt yeast, suggesting that CPR6 is not as
important as CPR7 in regulation of NoV replication in yeast. We
found similar pattern with FHV (Figure 8E), which is closely
related to NoV, that CPR7 deletion has a bigger effect than CPR6
deletion on virus replication. Overall, these experiments confirmed
that replication of two insect RNA viruses is also affected by
Cpr7p, and that Cpr7p can interact with the replication protein of
NoV in yeast. Therefore, it is possible that replication of other
RNA viruses could be regulated by Cyp40 proteins.
Figure 7. Binding of Cpr7p to TBSV p33 protein derivatives in vitro. (A) Schematic representation of viral p33 and its derivatives used in the
binding assay. The various domains include: TMD, transmembrane domain; RPR, arginine-proline-rich RNA binding domain; P; phosphorylated serine
and threonine; S1 and S2 subdomains involved in p33:p33/p92 interaction. (B) Affinity binding (pull-down) assay to detect interaction between FLAG-
Cpr7p and the MBP-tagged viral p33 protein derivatives. The MBP-tagged viral proteins and MBP produced in E. coli were immobilized on amylose-
affinity columns. Then, FLAG-Cpr7p expressed in BY4741 yeast was passed through the amylose-affinity columns with immobilized MBP-tagged
proteins. The affinity-bound proteins were eluted with maltose from the columns. The eluted proteins were analyzed by Western blotting with anti-
FLAG antibody to detect the amount of FLAG-Cpr7p specifically bound to MBP-tagged viral proteins. (C) Pull-down assay to detect interaction
between FLAG-Cpr7p, FLAG-Cpr6p and the MBP-tagged p33CDRPR, a mutated viral p33 protein lacking the RPR motif that binds to the viral RNA. See
further details in Panel B.
doi:10.1371/journal.ppat.1002491.g007
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Discussion
Genome-wide screens and global proteomics approaches with
tombusviruses unraveled many host proteins that can facilitate or
inhibit virus infections [9,11,22–24,29,39,49,50]. One group of
these host factors is cyclophilins, a large family of peptidyl-prolyl
cis-trans isomerases with protein chaperone-like function that play a
global role in facilitating correct protein folding and conforma-
tional changes in client proteins [40,41]. Isomerization of peptidyl-
prolyl bonds is frequently required for protein refolding,
maturation and trafficking. Cyclophilins share a common 109 aa
cyclophilin-like domain (CLD) performing the PPIase activity and
additional domains unique to each member of the family. The
unique domains, such as the TPR domain, are important for
selection of protein substrates and subcellular compartmentaliza-
tion. S. cerevisiae and Arabidopsis have 8 and 29 cyclophilins,
respectively, while humans have 16 cyclophilin isoforms that have
different cellular and tissue distribution [41,43,51].
We have found that four yeast cyclophilins (Cpr1p, Cpr3p,
Cpr6p and Cpr7p), in addition to Fpr1p (Figure 1) and Ess1p
PPIases [39], interacted with p33. CFEs prepared from a yeast
strain lacking these genes (except ESS1, which is essential for yeast
growth) supported TBSV replication in vitro at a higher level than
CFE from wt yeast, or a yeast strain lacking the remaining
noninteracting members of cyclophilin and FKB genes. Altogeth-
er, the data firmly established that the group of cyclophilins that
interacts with p33 is a robust negative regulator of TBSV
replication. Among the cyclophilins, we have discovered that the
yeast Cyp40-like Cpr7p strongly inhibits TBSV replication in yeast
model host and in vitro in a TBSV replication assay based on CFE.
Three Cyp40-like proteins from Arabidopsis plant also interacted
with p33/p92 replication proteins and they showed remarkable
inhibitory effect on TBSV repRNA accumulation when added to
the CFE-based replication assay (Figure 3C and Figure S3). Thus,
the inhibitory effect of Cyp40-like proteins against TBSV is
conserved between S. cerevisiae and Arabidopsis. Also, it seems that
Cpr7p can also inhibit the replication of insect RNA viruses NoV
and FHV (Figure 8) [52], which are distantly related to TBSV.
Based on these data, we propose that Cyp40-like proteins could be
Figure 8. Increased NoV and FHV RNA accumulation in cpr7D yeast. Split ubiquitin MYTH assay was used to test binding between the yeast
cyclophilins and NoV protein A (panel A), TMV 130K (panel B) and TCV p28 (panel C) replication proteins. The bait proteins were co-expressed with
the prey cyclophilin proteins in yeast. The empty prey vector (NubG) was used as a negative control. To launch NoV (panel D) or FHV RNA1 (panel E)
replication, we expressed NoV RNA1 from the copper-inducible CUP1 promoter and FHV RNA1 and DI634 from the CUP1 promoter in the parental
(BY4741) and in cpr6D, and cpr7D single deletion and cpr6D cpr7D double deletion yeast strains. The yeast cells were cultured for 48 hours at 29uC in
3 ml SC-H2 with 2% glucose media containing 50 mM CuSO4 (for NoV) and for 24 hours at 29uC in 3 ml SC-H2 with 2% galactose (for FHV). Northern
blot analysis was used to detect RNA1/RNA3 accumulation for NoV and FHV. The accumulation level of NoV and FHV RNAs was normalized based on
18S rRNA. Each experiment was repeated.
doi:10.1371/journal.ppat.1002491.g008
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important inhibitors or regulators of various RNA viruses.
Interestingly, Cyp40 is required for the activity of microRNAs in
plants [53]. Thus, in addition to the regulatory role in RNA
viruses, Cyp40 is also involved in other RNA-based processes.
The inhibitory effect of Cpr7p on TBSV replication seems to
depend on the TPR-domain, which can specifically bind to the
RNA-binding region of p33/p92 replication proteins of TBSV
(Figure 7). Indeed, Cpr7p or the TPR domain: p33 interaction
inhibits the recruitment of the viral RNA to membranes (Figure 9),
where viral replication takes place. In addition, Cpr7p also inhibits
the assembly of the functional VRC in vitro (Figure 9), which then
leads to decreased level of viral RNA synthesis [both (+) and
(2)RNA synthesis is inhibited proportionately, Figure 5E].
Inhibition of VRC assembly could be due to binding of Cpr7p
to the RPR RNA binding motif, thus inhibiting the RNA binding
activity of p33 and p92. Without the bound (+)RNA, p33 and p92
cannot assemble functional VRC since multiple cis-acting elements
within the TBSV (+)RNA are essential for VRC assembly [36,54].
However, we cannot exclude that Cpr7p might inhibit VRC
assembly indirectly via inhibition of viral (+)RNA recruitment,
Figure 9. Models for the role Cpr7p in tombusvirus replication. Model 1: Cpr7p has been shown to inhibit the recruitment of the viral RNA
into replication. Model 2: The assembly of the tombusviral VRC requires interactions among the viral replication proteins, selected host proteins, such
as Hsp70, GAPDH or eEF1A or membrane lipids. Cpr7p might inhibit any of these interactions, resulting in reduced TBSV RNA replication. In addition,
Cpr7p binds to the RPR RNA binding motif in p33 and likely inhibiting p33: viral (+)RNA interaction that is needed for VRC assembly. Model 3: Due to
the chaperone activity of the TPR domain, binding of Cpr7p to p92 might inhibit the RdRp function of p92, thus blocking RNA synthesis. See further
details in the text.
doi:10.1371/journal.ppat.1002491.g009
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which is required for VRC assembly [20,36]. In addition,
recombinant Cpr7p binding to the purified tombusvirus replicase
also results in reduced RNA synthesis in vitro, indicating that Cpr7p
can block viral RNA replication at several steps (Figure 9).
Interestingly, Cpr7p cannot efficiently inhibit the pre-assembled,
membrane-bound TBSV replicase in a CFE-based assay
(Figure 4C), suggesting that Cpr7p has to be present at the early
stage of replicase assembly for robust inhibition. It is likely that the
membrane-bound VRC might not be accessible for Cpr7p after
the VRC assembly is completed in CFE.
Similar to Cpr7p, another Cyp40-like protein (i. e., Cpr6p with
38% sequence identity with Cpr7p) can also bind to p33/p92
replication proteins (Figure 1 and S2B). However, this binding
does not lead to significant inhibition of TBSV replication in yeast
(Figure 2) or in the CFE-based TBSV replication assay (Figure
S1C). Since the Cpr6p : p33 interaction does not involve the
RNA-binding region in p33 (Figure S2B), we propose that this
interaction is less inhibitory to TBSV replication by likely allowing
p33 to perform its important functions in viral RNA recruitment
and VRC assembly as well as its RNA chaperone activity [33,55].
Another possibility for the weak inhibitory effect of Cpr6p is its low
chaperone activity. Accordingly, it has been shown that Cpr6p
and Cpr7p have different activities: Cpr6p is far more active as a
PPIase, while Cpr7p is a much better chaperone than Cpr6p [56].
Indeed, CPR6 could not complement the growth defect caused by
deletion of CPR7 in yeast and the defined functions of Cpr7p in
signaling and HSP90 binding are dependent on the TPR domain
[56–58]. Interestingly, Cpr6p can also interact with protein A of
NoV without effective inhibition of NoV replication (Figure 8).
Thus, it seems that Cpr6p has evolved different functions from
Cpr7p, including the regulatory role in viral RNA replication. In
contrast, all three Arabidopsis Cyp40-like proteins are inhibitory to
TBSV replication in vitro (Figure 3), suggesting that plants might
have more cyclophilins to combat some viral infections than yeast
does.
Similar to our findings with Cyp40 homologs, other cyclophilins
have been shown to inhibit accumulation of several RNA viruses.
For example, CypA was found to bind to the matrix protein (M1)
of influenza A virus and interfered with the nuclear localization of
M1 [59]. Over-expression of CypA increased the self-association
of M1 protein and led to decreased viral replication. Similarly,
CypA was also found to inhibit the infectivity of HIV-1 (human
immunodeficiency virus-1) virions [60,61]. Interestingly, due to
retrotransposition of CypA between exon 7 and 8 in TRIM5 gene in
New World owl monkeys, a CypA-TRIM5 fusion protein has
emerged, which targets the HIV-1 coat protein causing resistance
to HIV-1 infections [62,63]. CypA gets incorporated into HIV-1
virions via direct binding to Gag, the polyprotein precursor of
virion structural proteins [61,64,65]. The role of CypA as an anti-
HIV protein is neutralized by the retroviral Vif protein, which
inhibits the incorporation of CypA into the viral particles [66]. A
genome-wide screen for host factors affecting West Nile virus
identified FKBP1B immunophilin as an inhibitor of this virus [67].
Overall, cyclophilins/immunophilins are potent inhibitors of
several RNA viruses and they might be part of the innate response
of the host against some viruses. Since PPIases are conserved and
ubiquitous proteins, their role could be common against viruses.
On the contrary, several RNA viruses seem to hijack
cyclophilins to facilitate their replication. For example, cyclospor-
ine, an inhibitory peptide of cyclophilins, markedly inhibited HCV
replication in cell cultures [68,69]. It has been proposed that the
cytosolic CypA affects the assembly of the HCV VRC by likely
influencing the cleavage of NS5A-NS5B fusion protein and the
folding of the NS5A and NS5B RdRp proteins [70–72]. CypA
seems to affect multiplication of several flaviviruses, such as WNV,
Dengue virus and yellow fever virus [73]. CypA was shown to bind
to the NS5 replication protein and is likely component of the VRC
and cyclosporine has been shown to inhibit flaviviral RNA
synthesis [73].
The human FKBP8 immunophilin, which interacts via the
three TPR repeats with the HCV NS5A is also important for
HCV replication [74]. FKBP8 might function in HCV replication
by forming a complex between NS5A, FKBP8 and Hsp90 [74].
Interaction between NS5A and FKBPs is also important for HCV
to block apoptosis in hepatoma cells [75].
Overall, cyclophilins and other PPIases seem to play important
roles during RNA virus infections. The current work revealed a
new role for Cyp40-like proteins and their TPR domains as
inhibitors and regulators of RNA virus replication. This function
for Cyp40 seems to be conserved between yeast and plants and
also effective against tombus- and alfanodaviruses.
Materials and Methods
Yeast strains and expression plasmids
The following yeast strains with deletion of various cyclophilin
genes were used in this study: the wild type #149 (JK93da); 163:
KDY81.18C (fpr1-4D);164: KDY97.19 (cpr1-8D); 165: SMY101-1
(cpr2,4,5,8D/fpr2D); 166: KDY98.49 (cpr1-8D/fpr1-4D) (generous
gift of Joseph Heitman) [76]. Yeast strain 168 (cpr1,3,6,7D/fpr1D)
was created by homologous recombination based on strain
KDY75.3b using the HYG gene to replace CPR3. PCR was
performed using plasmid pFA6-hphNT1 (EUROSCARF) [77] as
template and primer set #3279/#3280 (Table S1). The PCR
product was transformed to KDY75.3b yeast strain and
recombinant yeast colonies were selected in SC-LA2 plates
supplemented with G418 and hygromycin.
The plasmids pHisGBK-CUP-His33/GAL-DI72 and pGAD-
CUP-Hisp92 used for viral replication experiments in yeast, have
been previously described [26,78]. Plasmids pGAD-ADH-HFp92,
pYC-GAL-DI72, and pHisGBK-ADH-HFp33 were generated by
Serva and Nagy [25].
To generate the Escherichia coli expression plasmids for GST-
CPR7 and its truncated derivatives, CPR7-CYP and CPR7-TPR,
we PCR-amplified the full-length sequence of CPR7 as well as
CPR7-CYP and CPR7-TPR domains (Figure 3B) with primer sets
#3152/#4116, #3152/#4132, and #4131/#4116, respectively.
To generate the E. coli expression plasmids for GST-At5g48570
and GST-At5g48570-TPR, we PCR amplified the full-length
sequence of At5g48570 and At5g48570-TPR with primer sets
#4332/#4333 and #4374/#4375 (Table S1), respectively. The
PCR products were digested with BamHI and EcoRI and ligated
into pGEX-2T using the same enzymes.
The FHV expression plasmid pESC-His/gal/FHV/RNA1 has
been generated before [48]. To launch NoV RNA1 replication in
yeast, we generated plasmid pEsc-His/Cupm/NoV/RNA1/
TRSVrz that expressed the full-length NoV RNA1 via cleavage
of the transcribed RNA1 at the 39 end by a ribozyme, similar to
the strategy used for FHV RNA1 expression [48]. Three PCR
products were ligated to each other in a stepwise fashion. The first
fragment was amplified from pGAD/CupHis92 with primers
#3873 and #3861 to obtain a modified CUP1 promoter with a
predicted transcriptional start site at or around the first viral
nucleotide. The second fragment was amplified from pMT/
NoVRNA1 (provided by SW Ding) with primers #3862 and
#3863 to obtain the full-length cDNA for NoV RNA1. The third
fragment was generated with primers #3871 and #3875 from
pYC/DI72/sat to amplify the ribozyme. The PCR reactions were
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carried out with Phusion polymerase. Primers #3861, #3862,
#3863 and #3871 were kinased with T4 polynucleotide kinase
prior to PCR. The final PCR was carried out with primers #3873
and #3875 using High Fidelity Taq polymerase (Invitrogen). The
resulting PCR product was digested with BglII and NheI and
cloned into pEsc-His (Agilent) digested with BamHI and BcuI.
Analysis of protein-protein interaction using the
split-ubiquitin assay
The split-ubiquitin assay is based on the Dualmembrane kit3
(Dualsystems) and performed as previously described [39,79]. The
bait constructs, pGAD-BT2-N-His33 and pGAD-BT2-N-His92,
expressing tombusvirus replication proteins p33 and p92,
respectively, were as described [26,39]. The CPR7 and the
truncated PCR products of CPR7 were digested with BamHI and
NheI and ligated into the pPRN-N-RE (Dualsystems) vector
digested with the same enzymes to generate pPRN-N-CPR7.
Yeast strain NMY51 was co-transformed with pGAD-BT2-N-
His33 and pPR-N-RE (NubG, as a negative control) or one of the
prey-constructs (pPR-N-CPR7) and plated onto Trp2/Leu2
(TL2) synthetic minimal medium plates for plasmid selection.
Yeast colonies were then re-suspended in 50 ml water and spotted
onto Trp2/Leu2/His2/Ade2 (TLHA2) plates to detect p33 :
Cpr7p interactions as described [26]. Plasmid expressing Ssa1p
protein (pPR-N-SSA1) was used as a positive control as previously
described [39,79].
Analysis of protein-protein interaction in vitro
The MBP-tagged p33 and p33C were purified from E. coli as
described previously [80]. E. coli cells were resuspend in cold
column buffer (10 mM Tris-HCl [pH 7.4], 1 mM EDTA, 25 mM
NaCl, 10 mM b-mercaptoethanol) and broken by sonication. The
cleared lysate was passed through an amylose column to bind the
MBP-tagged viral proteins or MBP (negative control). The
columns were washed three times with cold column buffer prior
to addition of the yeast lysate. For the pull-down assay, 100 mg of
yeast pellets containing FLAG-tagged Cpr7p (pESC-His-CupFlag-
CPR7) or its truncated forms were resuspended in 150 ml pre-
chilled Buffer I (20 mM Tris-HCl [pH 7.5], 1 mM EDTA,
200 mM NaCl, 10% [V/V] glycerol, 0.1% [V/V] NP40,
10 mM b-mercaptoethanol, 1% [V/V] yeast protease inhibitor
cocktail (Ypic)]) and 1 ml of RNase A (1 mg/ml). Yeast cells were
broken in Genogrinder with 250 ml volume of acid washed glass
beads for 2 min at 1,500 rpm followed by addition of 600 ml of
Buffer I. The yeast lysate was centrifuged at 1006 g at 4uC for
5 min, and the supernatant was transferred to a pre-chilled
eppendorf tube and centrifuged at 15,000 rpm at 4uC for 5 min
before loading onto the amylose columns and incubated for 3 h at
4uC. The columns were washed five times with cold column buffer
II (20 mM Tris-HCl [pH 7.5], 1 mM EDTA, 100 mM NaCl,
10% [V/V] glycerol, 0.1% [V/V] NP40), and the bound protein
complexes were eluted with column buffer supplemented with
10 mM maltose. The presence of FLAG-Cpr7p protein in the
eluate was analyzed by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) followed by Western blotting using
an anti-Flag antibody (Sigma). The amount of MBP-tagged viral
proteins in the eluate was visualized by Coomassie blue staining of
the 12% SDS-PAGE gels.
Analysis of TBSV, NoV and FHV RNA replication in yeast
For measuring TBSV repRNA accumulation, yeast strain BY4741,
cpr6D, cpr7D, and cpr6,7D were transformed with plasmids pGAD-
CUP-Hisp92, pHisGBK-CUP-Hisp33/GAL-DI72. Replication
assay was performed by measuring the accumulation of DI-72(+)
repRNA (normalized to the 18S rRNA). Replication was induced by
adding 50 mM CuSO4 to the SC-LH
2 medium and then yeast was
cultivated for 24 h at 23uC or 29uC. For measuring NoV RNA1/3
accumulation, yeast strain BY4741, cpr6D, cpr7D, and cpr6,7D were
transformed with plasmid pESC-His/Cupm/NoV/RNA1/TRSVrz.
Replication was induced by adding 50 mM CuSO4 to the SC-H
2
medium containing 2% glucose and then yeast was cultured for 48 h
at 29uC. For measuring FHV RNA1/3 accumulation, yeast strain
BY4741, cpr6D, cpr7D, and cpr6,7D were transformed with plasmids
pESC-URA/Cupm/FHV/DI634/TRSVrz and pESC-His/Gal/
FHV/RNA1/TRSVrz. Replication was induced by adding 50 mM
CuSO4 to the SC-UH
2 medium containing 2% galactose and then
yeast was cultured for 24 h at 29uC.
Yeast CFE-based TBSV replication assay
The different yeast strains used for preparation of CFEs were
grown in YPD medium at 29uC for 6–8 h to a final OD 1.5
followed by 30 min at 37uC before harvest and prepared as
described [31]. A total reaction volume (25 ml) contained 3 ml of
whole cell extract, 0.5 mg DI-72 (+)repRNA transcript, 700 ng
purified MBP-p33, 1.4 mg purified MBP-p92pol (both recombinant
proteins were purified from E. coli, see below), 30 mM HEPES-
KOH, pH 7.4, 150 mM potassium acetate, 5 mM magnesium
acetate, 0.13 M sorbitol, 0.4 ml actinomycin D (5 mg/ml), 2 ml of
150 mM creatine phosphate, 0.2 ml of 10 mg/ml creatine kinase,
0.2 ml of RNase inhibitor, 0.2 ml of 1 M dithiothreitol (DTT), 2 ml
of 10 mM ATP, CTP, and GTP and 0.25 mM UTP and 0.1 ml of
[32P]UTP [35]. The reaction mixture was incubated at 25uC for
3 h and terminated by adding 100 ml stop buffer (1% sodium
dodecyl sulfate [SDS] and 0.05 M EDTA, pH 8.0) followed by
phenol-chloroform extraction, isopropanol-ammonium acetate
precipitation overnight at 220uC and a washing step with 70%
ethanol as described [81]. The newly synthesized 32P-labeled RNA
products were separated by electrophoresis in a 5% polyacryl-
amide gel (PAGE) containing 0.56 Tris-borate-EDTA (TBE)
buffer with 8 M urea. Signals were detected using a Typhoon
9400 imaging scanner (Amersham) and quantified by imageQuant
software.
Testing the effect of recombinant Cpr7 in yeast
CFE-based TBSV replication assay
Reaction mixtures for in vitro replicase assays were set-up
according to the in vitro replication assay previously described
[31,35] with the following modification. In addition to the
recombinant viral replication proteins, MBP-p33 and MBP-
p92pol, 800 ng of GST-Cpr7p or its deletion derivatives were also
included in the assay. Reactions containing only GST and CFE
served as negative control. The assays included increasing
amounts (0.4, 0.8 and 1.6 mg) of purified recombinant proteins,
such as GST-Cpr7p (5.6, 11.3 and 22.5 mM), GST-CYP (7.6, 15.3
and 30.5 mM), GST-TPR (8.3, 16.7 and 33.4 mM) or GST (15.4,
30.7 and 61.5 mM).
Protein purification from E. coli
Expression and purification of the recombinant TBSV p33 and
p92 replication proteins from E. coli were carried out as described
earlier with modifications [80,82]. The expression plasmids were
transformed separately into E. coli strain BL21DE3CodonPlus.
Protein expression was induced using isopropyl b-D-thiogalacto-
pyranoside (IPTG) for 8 h at 16uC, and the cells were harvested by
centrifugation at 5,000 rpm at 4uC for 5 min to remove the
medium prior to 280uC storage. Affinity columns containing
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amylose resin (NEB) were used to purify MBP-tagged recombinant
proteins as described [80,82]. Purification of GST-tagged proteins
(pGEX-) was carried out using glutathione resin and eluted with
10 mM glutathione, 10 mM ß-mercaptoethanol in the column
buffer following the same protocol as MBP-proteins. Briefly, the
frozen pellets were suspended and sonicated in MBP column
buffer containing 20 mM Tris-Cl pH 8.0, 150 mM NaCl, 1 mM
EDTA, 10 mM b-mercaptoethanol and 1 mM phenylmethylsul-
fonyl fluoride (PMSF). The sonicated extract was centrifuged at
15,000 rpm for 5 min, and the supernatant was added to the pre-
equilibrated amylose resin for 1 h rotating incubation at 4uC.
After washing the resin 3 times with column buffer and once with
a low salt column buffer (25 mM NaCl), the proteins were eluted
with a low salt column buffer containing 0.18% (V/W) maltose
and 6% (V/V) glycerol and aliquoted for storage at 280uC. The
concentration of the purified recombinant proteins was measured
by Bio-Rad protein assay. Protein fractions used for the replication
assays were 95% pure, as determined by SDS-PAGE.
In vitro tombusvirus replicase assay with affinity purified
replicase preparations
Yeast BY4741 strain was transformed with the plasmids pGAD-
ADH-HFp92, pYC-GAL-DI72, and pHisGBK-ADH-HFp33
expressing 6xHis- and Flag-tagged tombusvirus p33 and p92.
Initially, yeast transformants were grown in 10 ml of ULH2
selective medium overnight at 30uC then transferred to fresh
200 ml ULH2 medium to 0.2 OD600 and grown at 23uC until 1.5
OD600. FLAG-affinity-purification was done according to a
previously described procedure with the following modification
[24]. Briefly, 2 g of yeast cells were resuspended and homogenized
in TG buffer [50 mM Tris–HCl [pH 7.5], 10% glycerol, 15 mM
MgCl2, 10 mM KCl, 0.5 M NaCl, 0.5% Triton, and 1% [V/V]
yeast protease inhibitor cocktail (Ypic)] by glass beads using
FastPrep Homogenizer (MP Biomedicals). The yeast cell lysate
was cleared by centrifugation at 5006 g for 5 min at 4uC to
remove unbroken cells and debris. The membrane fraction
containing the viral replicase complex was collected by centrifu-
gation at 35,0006g for 15 min at 4uC and then solubilized in 1 ml
TG buffer with a buffer containing 2% Triton, 1% [V/V] Ypic via
gentle rotation for 3 h at 4uC. The solubilized membrane fraction
was centrifuged at 35,0006 g for 15 min at 4uC and the
supernatant was incubated with 100 ml anti-FLAG M2-agarose
affinity resin (Sigma) pre-equilibrated with 1 ml TG buffer. After
3 h of gentle rotation at 4uC, the column was washed 5 times with
TG buffer containing 0.5% Triton. The resin-bound replicase
complex was eluted in 700 ml elution buffer [50 mM Tris–HCl
[pH 7.5], 10% glycerol, 15 mM MgCl2, 10 mM KCl, 0.05 M
NaCl, 0.5% Triton, 1% Ypic and 0.15 mg/ml FLAG peptide
(Sigma)] following overnight rotation at 4uC. In vitro replicase
activity of the purified preparations was tested using DI-72(2)
RNA template transcribed in vitro by T7 transcription [24].
In vitro viral RNA recruitment assay
The in vitro RNA recruitment assay based on yeast CFE was
performed according to [31,35], except that 32P-labeled DI72 (+)
repRNA were used and rCTP, rUTP, 32P-labeled UTP, and
Actinomycin D were omitted from the assay. As a negative
control, GST protein purified from E. coli was used in yeast CFE in
the absence of p33/p92. Following two-hour incubation at 25uC,
1 ml of reaction buffer was added to the in vitro reaction mixture
and further incubated on ice for 10 min before centrifugation at
35,0006 g for 45 min. The membrane-bound 32P-labeled
(+)repRNA was extracted from the pellet by adding 0.1 ml stop
buffer and 0.1 ml phenol/chloroform followed by brief vortex at
high setting and centrifuged at 27,0006 g for 4 min. The
supernatants from each reaction were precipitated with isopropa-
nol/ammonium acetate overnight at 220uC. The RNA samples
were analyzed by denaturing PAGE and phosphoimaging as
described [31,35].
Northern and Western blot analyses
Total-RNA isolation and Northern blot analysis were per-
formed as described previously [21]. The probes for Northern blot
to detect FHV RNA1/RNA3 (annealing to the 39 end of FHV
RNA1) and NoV RNA1/RNA3 (annealing to the 39 end of NoV
RNA1) was obtained via T7 transcription on PCR templates
generated by using the following primers: #3676 and #3675 (for
FHV) and #3867 and #3868 (for NoV) (Table S1).
Protein analysis was performed as described previously using an
anti-His6 antibody [20] as the primary antibody for the detection
of His6-p33 and His6-p92. Detection of FLAG-CPR7 and its
truncated derivatives were carried out using primary anti-FLAG
antibody following the manufacturer’s instructions (Sigma). The
secondary antibody for both primary antibodies was alkaline
phosphatase-conjugated anti-mouse immunoglobulin G (Sigma).
Additional Materials and Method section is available as Text
S1.
Supporting Information
Figure S1 CFE-based TBSV replication assay demonstrates an
inhibitory role for Cpr3p and Cpr7p. (A) Top panel: Denaturing
PAGE analysis of the 32P-labeled TBSV repRNA products
obtained in the CFE-based assay programmed with in vitro
transcribed TBSV DI-72 (+)repRNA and purified recombinant
p33 and p92pol replication proteins of TBSV. Purified recombi-
nant MBP-tagged Cpr1p, Cpr3p, Cpr7p, and Fpr1p (0.1, 0.2 and
0.4 mg), or MBP were added to CFE prepared from BY4741 yeast
strain. Each experiment was repeated three times. Bottom panel:
Ethidium-bromide stained PAGE gel from the top panel to show
the sample loading and the lack of RNase activity in the CFE-
based assay. (B) SDS-PAGE analysis of the purified recombinant
proteins used in the above CFE-based assay. (C) Denaturing
PAGE analysis of the 32P-labeled TBSV repRNA products
obtained in the CFE-based assay programmed with in vitro
transcribed TBSV DI-72 (+)repRNA and purified recombinant
p33 and p92pol replication proteins of TBSV. Two-step purified
recombinant 6xHis-GST-tagged Cpr6p and Cpr7p (0.4, 0.8 and
1.6 mg), or GST were added to CFE prepared from BY4741 yeast
strain. Each experiment was repeated three times. See additional
details in Panel A. (D) SDS-PAGE analysis of the two-step purified
recombinant 6xHis-GST-tagged Cpr6p and Cpr7p proteins used
in the above CFE-based assay.
(EPS)
Figure S2 Binding of Cpr6p to TBSV p33 protein derivatives.
(A) Split ubiquitin assay was used to test binding between p33 and
the full-length Cpr6p and its two domains (Cyp and TPR,
respectively). The bait p33 was co-expressed with the prey proteins
in yeast. Ssa1p (HSP70 chaperone), and the empty prey vector
(NubG, shown as ‘‘-control’’) were used as positive and negative
controls, respectively. (B) Schematic representation of viral p33
and its derivatives used in the binding-assay. The various domains
include: TMD, transmembrane domain; RPR, arginine-proline-
rich RNA binding domain; P; phosphorylated serine and
threonine; S1 and S2 subdomains involved in p33:p33/p92
interaction. (C) Affinity binding (pull-down) assay to detect
interaction between FLAG-Cpr6p and the MBP-tagged viral
p33 protein derivatives. The MBP-tagged viral proteins and MBP
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produced in E. coli were immobilized on amylose-affinity columns.
Then, FLAG-Cpr6p expressed in BY4741 yeast was passed
through the amylose-affinity columns with immobilized MBP-
tagged proteins. The affinity-bound proteins were eluted with
maltose from the columns. The eluted proteins were analyzed by
Western blotting with anti-FLAG antibody to detect the amount of
FLAG-Cpr6p specifically bound to MBP-tagged viral proteins. (D)
Detection of CPR7 mRNA levels in various yeast strains by semi-
quantitative RT-PCR. The top panel shows an ethidium-bromide-
stained 1.5% agarose gel of the semi-quantitative RT-PCR
products. The bottom panel shows an ethidium-bromide-stained
1.5% agarose gel of the total RNAs as loading controls.
(EPS)
Figure S3 CFE-based TBSV replication assay demonstrates an
inhibitory role for the Arabidopsis Cyp40-like proteins. (A)
Denaturing PAGE analysis of the 32P-labeled TBSV repRNA
products obtained in the CFE-based assay programmed with in
vitro transcribed TBSV DI-72 (+)repRNA and purified recombi-
nant p33 and p92pol replication proteins of TBSV. Purified
recombinant GST-tagged full-length Cyp40s or their TPR
domains (0.4, 0.8 and 1.6 mg), were added to CFE prepared from
BY4741 yeast strain. Each experiment was repeated three times.
(B–C) Split ubiquitin MYTH assay was used to test binding
between the TPR domain of three Arabidopsis Cyp40 proteins and
the TBSV p33 (panel B) and p92 (panel C) replication proteins.
The bait proteins were co-expressed with the prey cyclophilin
proteins in yeast. The empty prey vector (NubG) was used as a
negative control. Note the weak, but detectable interaction
between At2g15790-TPR and p33/p92 proteins.
(EPS)
Figure S4 Split ubiquitin MYTH assay was used to test binding
between the yeast Cpr1p and the following viral replication
proteins: NoV protein A (panel A), TMV 130K (panel B), TCV
p28 (panel C) and the p33 of Cucumber necrosis virus (CNV, a
tombusvirus, closely related to TBSV) (panel D). The bait proteins
were co-expressed with the prey Cpr1p in yeast. The other three
host proteins were used as controls.
(EPS)
Table S1 The list of primers used in this study.
(DOC)
Text S1 Materials and methods.
(DOC)
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